25th Jul 2018 09:48
LONDON (Alliance News) - Clinigen Group PLC said Wednesday that it acquired the global rights to osteoporosis drug Imukin from Horizon Pharma PLC.
The FTSE 250 pharmaceutical company said it will make the drug, used to reduce infections in patients with chronic granulomatous disease and to treat severe malignant osteopetrosis, "available to those who need it" through its global distribution network.
Horizon will retain the rights to Actimmune, a similar drug, in the US, Canada and Japan.
Chronic granulomatous is a genetic life-threatening disease affecting white blood cells, which are unable to fight bacterial or fungal infections effectively.
Severe malignant osteopetrosis is a condition affecting the bones rendering them more brittle than normal.
Clinigen shares were trading down 0.1% at 958.46 pence each.
Related Shares:
CLIN.L